RenovoRx Publishes TAMP Case Series on LAPC Patients
RenovoRx announced a peer-reviewed case series detailing tumor response, CA 19-9 reductions, and favorable imaging changes after TAMP-mediated intra-arterial gemcitabine in two unresectable LAPC patients. No major procedural complications were reported.